Among the novel CSF-1R inhibitors emactuzumab, recombinant, humanized monoclonal antibody against CSF-1R, was tested in phase 1 trials in patients with urothelial bladder cancer (NCT01494688) [77] and diffuse-type tenosynovial giant cell tumors (dTGGT, NCT02323191) [78]. The gene discussed is CSF1R; the disease is bladder transitional cell carcinoma.